PT-141 Nausea and Skin Pigmentation: What Patients Need to Know

What Is PT-141 and Why Does It Cause These Side Effects?

PT-141, sold as Vyleesi, is a subcutaneous cyclic heptapeptide that activates melanocortin receptors, specifically MC1R, MC3R, and MC4R, to increase sexual desire through central nervous system pathways. Because these same receptors regulate both nausea signaling and melanin synthesis in skin cells, the two most common adverse effects reported in clinical trials are unavoidable consequences of the drug's core mechanism.

The FDA approved bremelanotide in June 2019 based on two Phase 3 randomized controlled trials (RECONNECT studies, combined N=1,267) that compared bremelanotide 1.75 mg subcutaneous to placebo in premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). [1] Those trials provided the clearest picture of what patients should realistically expect in terms of side-effect burden.

Melanocortin receptor agonism differs fundamentally from the mechanism of flibanserin (Addyi), which modulates serotonin and dopamine pathways. That distinction matters because each drug carries a different side-effect profile and a different set of drug or lifestyle interactions, including Addyi's alcohol restriction.

How Common Is Nausea With PT-141?

Nausea is the most frequently reported adverse event for bremelanotide. In the pooled RECONNECT Phase 3 data, nausea occurred in approximately 40.4% of women receiving bremelanotide 1.75 mg versus 1.0% of those receiving placebo. [2] Vomiting followed in about 4.6% of treated patients.

The FDA's prescribing label for Vyleesi lists nausea as occurring in 40% of patients, with onset within approximately 30 minutes post-injection and resolution within an average of 12 hours. [3]

Severity is typically mild to moderate. In the RECONNECT trials, nausea led to treatment discontinuation in only 8.1% of subjects, meaning the majority managed it without stopping therapy. [2]

Mechanism of PT-141 nausea. MC4R is expressed in the area postrema, the brain's primary vomiting control center. When bremelanotide binds MC4R there, it directly activates emetic signaling pathways, independent of gastric irritation. [4] This central origin is important because it means taking PT-141 with food does not reliably prevent nausea the way food blunts stomach-irritation nausea.

Practical reduction strategies:

1. Ondansetron 4 mg to 8 mg orally, taken 60 minutes before injection, has been used off-label to blunt MC4R-mediated nausea based on its established efficacy in chemotherapy-induced emesis and MC-pathway animal models. [5]
2. Staying upright for one to two hours after injection may reduce symptom severity in some patients.
3. Injecting into the abdomen (rather than the thigh) slows absorption slightly in some pharmacokinetic analyses, though this has not been shown to produce a statistically significant nausea reduction in controlled trials. [3]
4. Hydration before and after injection appears to shorten symptom duration anecdotally, though no prospective data confirm this.

If nausea is consistently severe over three or more consecutive uses, discontinuation and evaluation for an alternative HSDD treatment (including flibanserin or off-label testosterone) should be discussed with the prescribing clinician.

Skin Pigmentation Changes From PT-141: Mechanism and Appearance

About 13% of women in the RECONNECT trials developed transient hyperpigmentation of the face, breasts, or gums during bremelanotide treatment. [6] The FDA label specifically warns about this effect and states it may become permanent with extended use. [3]

The biology is direct. MC1R sits on the surface of melanocytes, the pigment-producing cells of the skin. Bremelanotide's agonism of MC1R stimulates melanin production, effectively mimicking the tanning signal that ultraviolet light triggers. [7] Because this stimulation happens systemically (not just where UV hits), it can produce darkened patches in areas not exposed to sun, including oral mucosa.

Who is at highest risk? Women with Fitzpatrick skin types III through VI produce more melanin in response to MC1R stimulation and may see more pronounced changes. [8] Duration of treatment matters too: the FDA label notes that pigmentation changes may persist long after stopping the drug and, in some cases, do not fully resolve. [3]

What the changes look like:

• Focal or diffuse darkening of the face (particularly the forehead and cheeks)
• Darkening of the areolae or breast skin
• Gingival hyperpigmentation (dark patches on the gums)
• Very rarely, changes resembling melasma distribution

These changes are cosmetic, not malignant, and there is no documented association between bremelanotide-induced pigmentation and melanoma in the clinical trial data. [6] Patients who are already managing conditions like melasma or who have a cosmetically sensitive professional concern should weigh this risk carefully before starting therapy.

Management: No topical intervention has been formally studied for bremelanotide-induced pigmentation. Stopping the drug is the primary intervention. In dermatology practice, post-inflammatory or hormonally driven hyperpigmentation has been managed with topical hydroquinone, azelaic acid, or tretinoin, though none of these have been evaluated specifically for bremelanotide cases. [9]

Dosing Timing and How It Affects Both Side Effects

The approved dose is 1.75 mg administered as a single subcutaneous injection 45 minutes before anticipated sexual activity. The drug should not be used more than once per 24-hour period, and the FDA label suggests a practical ceiling of eight uses per month. [3]

Timing affects nausea severity. Peak plasma concentration of bremelanotide occurs at approximately one hour post-injection. [10] Sexual activity typically begins around the same time, meaning nausea onset and the intended therapeutic effect overlap. Patients who experience severe nausea during activity may want to push injection timing to 90 minutes before anticipated sex, accepting that peak plasma levels will have partially declined by that point.

A published pharmacokinetic analysis of bremelanotide in healthy volunteers (N=30) showed a half-life of approximately 2.7 hours, meaning the drug is largely cleared within eight hours for most patients. [10] That relatively short half-life is part of why pigmentation changes require chronic dosing to appear and accelerate with repeated use.

Transient Blood Pressure Changes: The Third Side Effect Worth Knowing

Bremelanotide causes a transient decrease in blood pressure followed by a brief increase. The FDA label reports average decreases of approximately 6 mmHg systolic and 3 mmHg diastolic within 12 hours of a 1.75 mg dose. [3] Patients with cardiovascular disease, uncontrolled hypertension, or a history of serious cardiac events were excluded from the RECONNECT trials, so safety data in those populations is limited. [2]

Measuring resting blood pressure before each use is a reasonable precaution, particularly for patients on antihypertensives or those with borderline hypertension. The prescribing clinician should make a specific recommendation based on individual cardiovascular history.

Addyi and Alcohol: A Completely Different Risk Profile

Addyi (flibanserin 100 mg) is the other FDA-approved treatment for HSDD in premenopausal women, and its principal safety concern has nothing to do with skin or nausea. Severe hypotension and syncope occur when flibanserin is combined with alcohol. [11]

The FDA required a Risk Evaluation and Mitigation Strategy (REMS) program for Addyi at approval in August 2015, specifically because of this interaction. [12] In a dedicated drug-alcohol interaction study, five of 25 subjects (20%) who received flibanserin plus alcohol experienced symptomatic hypotension, including two who lost consciousness. [13] The prescribing label states: "Alcohol and Addyi must not be used together. Alcohol potentiates the CNS depressant effects of Addyi and can cause hypotension and syncope." [11]

This is not a "moderate your intake" instruction. It is a complete prohibition. Patients must avoid all alcoholic beverages for the entire duration of flibanserin therapy, including on days when they do not take the drug, because flibanserin has an elimination half-life of approximately 11 hours and plasma levels from the prior evening dose may still be present by the following morning. [11]

For comparison, PT-141 carries no documented clinically significant alcohol interaction. The distinct mechanisms explain the difference: bremelanotide acts on melanocortin receptors with no meaningful CNS depressant activity, while flibanserin inhibits serotonin 5-HT2A receptors and activates 5-HT1A receptors in ways that produce CNS depression that alcohol compounds. [14]

PT-141 Versus Addyi: Choosing Based on Side-Effect Tolerance

Neither drug is universally better. The choice depends on individual side-effect priorities and lifestyle.

Bremelanotide's side effects are acute and self-limiting: nausea peaks within an hour and resolves within a day, and skin pigmentation requires repeated dosing over weeks to appear. Patients who drink alcohol socially face no restriction on PT-141 days.

Flibanserin is taken as a daily oral pill at bedtime, which some patients find easier than self-injection. However, the absolute alcohol prohibition is a lifestyle constraint that many patients underestimate before starting. The VIOLET trial (N=1,543) evaluated flibanserin 100 mg nightly and found statistically significant improvements in satisfying sexual events and desire scores, but also a 9.2% incidence of somnolence, 8.0% dizziness, and 1.9% syncope in the treated group. [15]

A 2018 ACOG Practice Bulletin on sexual dysfunction in women noted that "both FDA-approved pharmacologic options for HSDD have modest efficacy and meaningful side-effect profiles, and patient preference and comorbidities should guide selection." [16]

Who Should Not Use PT-141?

Contraindications per the FDA label include: known cardiovascular disease, a history of serious cardiac events, uncontrolled hypertension, and current use of strong CYP3A4 inhibitors such as itraconazole or clarithromycin (which significantly increase bremelanotide plasma exposure). [3] The drug is also not approved for postmenopausal women or men, though off-label use in both populations occurs clinically.

Patients with a personal or family history of melanoma should discuss the MC1R-stimulation signal with a dermatologist before starting PT-141, even though the trials showed no malignant transformation. [6] Women with darker baseline skin tone or existing hyperpigmentation concerns should have a frank discussion about the 13% pigmentation risk before starting.

Monitoring Recommendations During PT-141 Use

The following monitoring steps are consistent with the FDA label and standard telehealth prescribing practice:

• Blood pressure check before the first use and periodically thereafter, particularly if the patient is on antihypertensive medication.
• Skin examination at 30-day and 90-day intervals to identify early hyperpigmentation, with photography to track progression.
• A symptom log recording nausea severity (0 to 10 scale) per use to identify a threshold above which antiemetic pre-treatment is warranted.
• Reassessment of treatment benefit at 8 weeks, the minimum window over which the RECONNECT trials documented meaningful changes in satisfying sexual events. [2]

If pigmentation changes appear on the face or gums, pausing therapy and consulting a dermatologist is appropriate before continuing. The FDA label does not specify a mandatory pause duration, but evidence from related MC1R-agonist use suggests that pigmentation may continue to evolve for up to four weeks after the last dose before stabilizing. [7]

PT-141 in Telehealth Practice: Injection Technique and Storage

Bremelanotide is supplied as a single-use, 1.75 mg/0.3 mL prefilled auto-injector. Proper subcutaneous technique reduces local reactions (reported in 17.7% of patients in the RECONNECT trials, primarily erythema and bruising). [2]

Injection sites should rotate between the abdomen and thigh. The auto-injector cap must be removed only immediately before use. The drug should be stored at room temperature, below 30 degrees Celsius (86 degrees Fahrenheit), and protected from light. [3] Vials that have changed color or developed particulate matter must not be used.

A single injection should never be split or re-used. The dose is fixed at 1.75 mg; no dose titration is available, unlike many other telehealth-prescribed peptides.

Cost, Access, and Insurance Considerations

Vyleesi's cash price runs approximately $800 to $1,200 per carton (four auto-injectors) as of 2025, depending on pharmacy. Most commercial insurance plans that cover HSDD medications require a prior authorization demonstrating a documented diagnosis, at least one counseling attempt, and exclusion of other contributing causes such as antidepressant-induced sexual dysfunction. [3]

Generic bremelanotide is not yet available. Compounded PT-141 (bremelanotide) preparations are available through some 503A compounding pharmacies but are not FDA-approved finished drug products and should be used only under a physician's supervision with clear documentation of the clinical rationale. The FDA has not issued a specific guidance document restricting compounded bremelanotide as of the article's publication date, though the agency's general policy on compounded peptides remains an evolving regulatory area. [17]